Mainz Biomed Engages Support for Study of mRNA Biomarkers for ColoAlert

 Results of European study potentially incorporated into U.S. regulatory strategy for FDA approval

Opportunity for ColoAlert to become the gold standard at-home screening test for colorectal cancer

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today it has formally contracted with DCN Dx, a leading international developer of point-of-care diagnostics, and provider of comprehensive product development services. An integral part of the engagement will be the role of Emily Friedland, Vice President of Clinical Research at DCN Dx, who will spearhead the preparation and initiation of Mainz’s European centric clinical study to evaluate the potential to integrate a portfolio of recently acquired novel mRNA biomarkers into ColoAlert, the Company’s highly efficacious, and easy-to-use detection test for colorectal cancer. This suite of biomarkers which were in-licensed from Socpra Sciences Santé Et Humaines S.E.C. (“TTS”) in early January 2022, have demonstrated the unique ability to detect pre-cancerous lesions including advanced adenomas (AA), a type of pre-cancerous polyp often attributed to colorectal cancer (CRC). The study is on track to commence in the first half of 2022.

https://finance.yahoo.com/news/mainz-biomed-engages-dcn-dx-080100019.html